Ventas, Inc. (VTR) Stock Rating Upgraded by Zacks Investment Research
According to Zacks, “Shares of Ventas underperformed the Zacks categorized REIT and Equity Trust – Other industry over the past 3 months. But, its 2017 estimates moved up over the past 7 days, indicating that there may be a reversal in the price movement. Recently, Ventas acquired a high-quality life science, research and medical campus in Providence, Rhode Island from affiliates of Blackstone Real Estate Partners VIII L.P. This acquisition not only enhances Ventas’ portfolio but also strengthens its partnerships with top research universities. Also, the company closed the secured debt financing of $700 million for Ardent Health Services’ acquisition of LHP Hospital. Ventas’ large and diversified healthcare portfolio is expected to help it benefit from an increasing healthcare spending, aging population and a rise in insured individuals. But, earnings dilutive impact of disposition, stiff competition and rise in interest rate are concerns.”
VTR has been the subject of several other research reports. Jefferies Group LLC restated a hold rating and set a $58.00 price target on shares of Ventas in a report on Tuesday, January 31st. BMO Capital Markets cut Ventas from a market perform rating to an underperform rating in a report on Tuesday, January 31st. Evercore ISI cut Ventas from a hold rating to an underperform rating in a report on Friday, March 3rd. Mizuho lowered Ventas from a buy rating to a neutral rating and set a $63.00 price objective for the company. in a research note on Monday, November 21st. Finally, Goldman Sachs Group Inc lowered Ventas from a neutral rating to a sell rating and set a $56.00 price objective for the company. in a research note on Wednesday, March 15th. Three research analysts have rated the stock with a sell rating and ten have given a hold rating to the stock. Ventas has a consensus rating of Hold and an average target price of $62.44.
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/ventas-inc-vtr-stock-rating-upgraded-by-zacks-investment-research.html
Ventas (NYSE:VTR) opened at 60.53 on Wednesday. The stock’s 50 day moving average price is $62.09 and its 200 day moving average price is $64.12. Ventas has a 1-year low of $56.20 and a 1-year high of $76.80. The stock has a market capitalization of $21.47 billion, a PE ratio of 32.60 and a beta of 0.08.
Ventas (NYSE:VTR) last released its quarterly earnings results on Friday, February 10th. The real estate investment trust reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. The business earned $875.70 million during the quarter. Ventas had a return on equity of 6.42% and a net margin of 18.85%. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.37 EPS. On average, equities research analysts predict that Ventas will post $1.70 earnings per share for the current fiscal year.
Your IP Address:
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 31st. Investors of record on Tuesday, March 7th will be paid a dividend of $0.775 per share. This represents a $3.10 dividend on an annualized basis and a dividend yield of 5.12%. The ex-dividend date of this dividend is Friday, March 3rd. Ventas’s dividend payout ratio is currently 166.67%.
Several large investors have recently modified their holdings of VTR. William Harris Investors Inc. raised its stake in shares of Ventas by 0.3% in the fourth quarter. William Harris Investors Inc. now owns 4,727 shares of the real estate investment trust’s stock worth $295,000 after buying an additional 15 shares in the last quarter. Capital Innovations LLC raised its stake in shares of Ventas by 0.4% in the third quarter. Capital Innovations LLC now owns 5,686 shares of the real estate investment trust’s stock worth $402,000 after buying an additional 20 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in shares of Ventas by 0.3% in the third quarter. Municipal Employees Retirement System of Michigan now owns 10,700 shares of the real estate investment trust’s stock worth $756,000 after buying an additional 30 shares in the last quarter. Newman Dignan & Sheerar Inc. raised its stake in shares of Ventas by 0.3% in the third quarter. Newman Dignan & Sheerar Inc. now owns 12,621 shares of the real estate investment trust’s stock worth $891,000 after buying an additional 33 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale raised its stake in shares of Ventas by 0.4% in the third quarter. DekaBank Deutsche Girozentrale now owns 12,116 shares of the real estate investment trust’s stock worth $866,000 after buying an additional 50 shares in the last quarter. 91.98% of the stock is owned by hedge funds and other institutional investors.
Ventas Company Profile
Ventas, Inc is a healthcare real estate investment trust (REIT) with its properties located throughout the United States, Canada and the United Kingdom. The Company operates through three segments: triple-net leased properties, senior living operations and MOB operations. In its triple-net leased properties segment, the Company acquires and owns seniors housing and healthcare properties throughout the United States and the United Kingdom.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ventas Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventas Inc. and related companies with MarketBeat.com's FREE daily email newsletter.